Skip to main content

A Case of a Papillary Thyroid Cancer with Lymph Node Metastases Found on Prophylactic Central Neck Dissection (Subclinical Disease, Micrometastases)

  • Chapter
Thyroid Cancer

Abstract

Occult papillary thyroid carcinoma (OPTC) has been defined as a PTC with a maximal tumor dimension of 1.5 cm or less with or without neck nodal metastases (NNM). It is increasingly prevalent, now accounting for the majority of PTCs diagnosed in the twenty-first century. About one in four is multicentric and one in three node-positive at presentation. Ninety-six percent are noninvasive and 99.5 % are localized to the neck. The majority are treated initially with near-total or total thyroidectomy, a minority by unilateral lobectomy. Therapeutic nodal dissection is performed for N1b disease. Controversy surrounds the role of prophylactic central compartment dissection with removal of subclinical level VI nodal metastases. Also, there is ongoing controversy regarding the acceptability of unilateral lobectomy as a definitive primary surgical procedure for OPTC. Radioiodine remnant ablation was performed in the 1980s in almost 50 % of OPTC patients, but currently, most (>80 %) do not receive ablative therapy, since it does not reduce recurrence rates at any site. Patients treated conventionally for OPTC can be reassured that they will enjoy a normal life expectancy and 90 % will never see a neck nodal recurrence during 40 years after initial surgery. It is probable that the observed excellent outcomes relate more to the indolent biologic nature of OPTC, rather than the efficacy of the variable initial management policies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

TSH:

Thyroid stimulating hormone thyrotropin

US:

Ultrasound

PTC:

Papillary thyroid carcinoma

cTNM:

Clinical tumor node metastasis

pTNM:

Postoperative tumor node metastasis

AJCC:

American Joint Committee on Cancer

UICC:

International Union Against Cancer

CSM:

Cause-specific mortality

AGES:

Age grade extent size

MACIS:

Metastases age completeness invasion size

AMES:

Age metastases extrathyroid size

NNM:

Neck nodal metastases

TST:

Thyroxine-suppressive therapy

Tg:

Thyroglobulin

RAI:

Radioactive iodine

RRA:

Radioiodine remnant ablation

WBS:

Whole body scan

CT:

Computerized tomographic

OPTC:

Occult papillary thyroid carcinoma

DM:

Distant metastases

BLR:

Bilateral lobar resection

RNR:

Regional neck recurrence

ATA:

American Thyroid Association

ETA:

European Thyroid Association

FDA:

Food and Drug Administration

BST:

Bilateral subtotal thyroidectomy

UL:

Unilateral lobectomy

NTT:

Near-total thyroidectomy

TT:

Total thyroidectomy

LRR:

Locoregional recurrence rate

R:

Recommendation

MSKCC:

Memorial Sloan Kettering Cancer Center

NCDB:

National cancer data base

SEER:

Surveillance epidemiology, and end results

References

  1. Woolner LB, Lemmon ML, Beahrs OH, Black BM, Keating Jr FR. Occult papillary carcinoma of the thyroid gland: a study of 140 cases observed in a 30-year period. J Clin Endocrinol. 1960;20:89–105.

    Article  CAS  Google Scholar 

  2. Hubert Jr JP, Kiernan PD, Beahrs OH, McConahey WM, Woolner LB. Occult papillary carcinoma of the thyroid. Arch Surg. 1980;115:394–8.

    Article  PubMed  Google Scholar 

  3. Thompson NW, Nishiyama RH, Harness JK. Thyroid carcinoma: current controversies. Curr Probl Surg. 1978;15:1–67.

    Google Scholar 

  4. Grant CS, Stulak J, Thompson GB, Richards ML, Reading CC, Hay ID. Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999–2006. World J Surg. 2010;34:1239–46.

    Article  PubMed  Google Scholar 

  5. Hay ID. Managing patients with a preoperative diagnosis of AJCC/UICC stage I (T1N0M0) papillary thyroid carcinoma: East versus West, whose policy is best? World J Surg. 2010;34:1291–3.

    Article  PubMed  Google Scholar 

  6. Grant CS. Papillary thyroid cancer: strategies for optimal individualized surgical management. Clin Ther. 2014;36:1117–26.

    Article  PubMed  Google Scholar 

  7. Nixon IJ, Shaha AR. Management of regional nodes in thyroid cancer. Oral Oncol. 2013;49:671–5.

    Article  PubMed  Google Scholar 

  8. Giordano D, Valcavi R, Thompson GB, Pedroni C, Renna L, Gradoni P, Brabieri V. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. Thyroid. 2012;22:911–7.

    Article  PubMed  Google Scholar 

  9. Paphasavit A, Thompson GB, Hay ID, Grant CS, van Heereden JA, Ilstrup DM, Schleck C, Goellner JR. Follicular and Hurthle cell thyroid neoplasms: is frozen-section evaluation worthwhile? Arch Surg. 1997;132:674–9.

    Article  Google Scholar 

  10. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 1986;61:978–96.

    Article  CAS  PubMed  Google Scholar 

  11. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma; a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088–95.

    CAS  PubMed  Google Scholar 

  12. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am. 1990;19:545–76.

    CAS  PubMed  Google Scholar 

  13. Rivera M, Ricarte-Filho J, Tuttle RM, Ganly I, Shaha A, Knauf J, Fagin J, Ghossein R. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid. 2010;20:1085–93.

    Article  PubMed  Google Scholar 

  14. Ito Y, Miyauchi A, Kihara M, Kobayashi K, Miya A. Prognostic values of clinical lymph node metastases and macroscopic extension in papillary thyroid carcinoma. Endocrinol J. 2014;61:745–60.

    Google Scholar 

  15. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg. 2006;30:780–6.

    Article  PubMed  Google Scholar 

  16. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1987;114:1050–8.

    Google Scholar 

  17. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–53.

    CAS  PubMed  Google Scholar 

  18. Hay ID. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic’s experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Assoc. 2002;113:241–60.

    Google Scholar 

  19. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94:692–700.

    Article  PubMed  Google Scholar 

  20. Hay ID. Management of patients with low-risk papillary thyroid carcinoma. Endocr Pract. 2007;13:521–33.

    Article  PubMed  Google Scholar 

  21. Randolph GW, Thompson GB, Branovan DI, Tuttle RM. Treatment of thyroid cancer 2007 – a basic review. Int J Radiat Oncol Biol Phys. 2007;69 Suppl 2:892–7.

    Google Scholar 

  22. Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol. 2002;178:699–704.

    Article  CAS  PubMed  Google Scholar 

  23. Heilo A, Sigstad E, Fagerlid KH, Haskjold OI, Groholt KK, Berner A, Bjoro T, Jorgensen LH. Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab. 2011;96:2750–5.

    Article  CAS  PubMed  Google Scholar 

  24. Hay ID, Lee RA, Davidge-Pitts C, Reading CC, Charboneau JW. Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected “recurrent” neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. Surgery. 2013;154:1448–55.

    Article  PubMed  Google Scholar 

  25. Hay ID, Mullan BP, McIver B, Maurer M, Powell CC, Oberg AL, Wiseman GA, Goellner JR, Gorman CA. Radioiodine remnant ablation does not decrease recurrence rates in patients with small papillary thyroid carcinomas. J Nucl Med. 2002;43 Suppl 5:12P.

    Google Scholar 

  26. Cappelli C, Castellano M, Braga M, Gandossi E, Pirola I, De Martino E. Aggressiveness and outcome of papillary thyroid carcinoma versus microcarcinoma: a mono-institutional experience. J Surg Oncol. 2007;95:555–60.

    Article  CAS  PubMed  Google Scholar 

  27. Hay ID, Hutchinson ME, Reinalda MS, Grant CS, McIver B, Thompson GB. Woolner’s “occult” papillary thyroid cancer revisited: 1421 cases treated at one institution during a 60-year period. Proceedings 90th Annual Meeting, Endocrine Society, San Francisco, CA; June 2008.

    Google Scholar 

  28. Nixon IJ, Ganly I, Patel SG, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Shah JP. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012;151:571–9.

    Article  PubMed  Google Scholar 

  29. Nixon IJ, Ganly I, Patel SG, Morris LG, Palmer FL, Thomas D, Tuttle RM, Shah JP, Shaha AR. Observation of clinically negative central compartment lymph nodes in papillary thyroid carcinoma. Surgery. 2013;154:1166–73.

    Article  PubMed  Google Scholar 

  30. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, Sherman SI, Tuttle RM, The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109–42.

    Article  PubMed  Google Scholar 

  31. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SL, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;11:1–48.

    Google Scholar 

  32. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff K, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015 (in press).

    Google Scholar 

  33. Hay ID, McDougall IR, Sisson JC. Perspective: the case against radioiodine remnant ablation in patients with differentiated thyroid carcinoma. J Nucl Med. 2008;49:1395–7.

    Article  Google Scholar 

  34. Mazzaferri EL. A vision for the surgical management of papillary thyroid carcinoma: extensive lymph node compartmental dissections and selective use of radioiodine. J Clin Endocrinol Metab. 2009;94:1086–8.

    Article  CAS  PubMed  Google Scholar 

  35. Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, Scheri R, Roman SA, Sosa JA. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260:601–7.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Abdelgadir AM, Pura J, Goffredo P, Dinan M, Hyslop T, Reed SD, Scheri RP, Roman SA, Sosa JA. Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. J Clin Endocrinol Metab. 2015;100:115–21.

    Article  Google Scholar 

  37. Grant CS. Recurrence of papillary thyroid cancer after optimized surgery. Gland Surg. 2015;4:52–62.

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ian D. Hay MD, PhD, FACE, FACP, FRCP .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Hay, I.D. (2016). A Case of a Papillary Thyroid Cancer with Lymph Node Metastases Found on Prophylactic Central Neck Dissection (Subclinical Disease, Micrometastases). In: Cooper, D., Durante, C. (eds) Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-22401-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22401-5_8

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22400-8

  • Online ISBN: 978-3-319-22401-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics